Results 221 to 230 of about 1,136,503 (270)

A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.

Expert Opinion on Biological Therapy, 2018
Psoriasis is a chronic inflammatory skin disease whose pathogenesis is driven by multiple cytokine-mediated pathways. In this immunologic setting, the centrality of the IL-23/IL-17 axis and its therapeutic relevance has emerged.This review is aimed at collecting preliminary data on IL23p19 blockers developed for the treatment of plaque psoriasis. Three
Annalisa Tonini, B. Gualtieri, S. Panduri, M. Romanelli, A. Chiricozzi   +4 more
semanticscholar   +5 more sources

Anti‐IL‐23 and Anti‐IL‐17 Biologic Agents for the Treatment of Immune‐Mediated Inflammatory Conditions

Clinical Pharmacology & Therapeutics, 2018
Advancements in the immunopathogenesis of psoriasis have identified interleukin (IL)‐23 and IL‐17 as fundamental contributors in the immune pathways of the disease. Leveraging these promising therapeutic targets has led to the emergence of a number of anti‐IL‐23 and ‐17 biologic agents with the potential to treat multiple conditions with common ...
Jillian Frieder, D. Kivelevitch, I. Haugh, Ian T Watson, A. Menter   +4 more
semanticscholar   +3 more sources

Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects.

Int. Journal of Clinical Pharmacology and Therapeutics, 2015
To evaluate the effect of ethnicity on the pharmacokinetics (PK) of tildrakizumab, a novel anti-IL-23 monoclonal antibody for the treatment of psoriasis.This was an open-label, 2-part study in healthy adult subjects. In part 1, Japanese subjects and matched Caucasian and Chinese subjects (to Japanese) were assigned to 1 of 3 cohorts and administered ...
A. Zandvliet, S. Glasgow, A. Horowitz, Diana Montgomery, J. Marjason, A. Mehta, Christine R. Xu, M. van Vugt, Sauzanne G Khalilieh   +8 more
semanticscholar   +3 more sources

Guselkumab. Anti-IL-23 antibody, Antipsoriatic

Drugs of the Future, 2017
J. Gras
semanticscholar   +2 more sources

New anti-IL-23 drugs raise hopes for psoriasis plaque clearance

Nature Biotechnology, 2016
E. Dolgin
semanticscholar   +3 more sources

Successful use of anti‐IL‐23 molecules in overweight‐to‐obese psoriatic patients: A multicentric retrospective study

Dermatologic Therapy, 2022
Advances in treatment with biological agents have changed the course of psoriasis. However observational reports and controlled trials draw attention to the heterogeneity of treatment response and point out that Body Mass index (BMI) may be a key factor ...
F. Ricceri, A. Chiricozzi, K. Peris, F. Prignano   +3 more
semanticscholar   +1 more source

Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies

AAPS Journal, 2019
The pro-inflammatory cytokine interleukin (IL)-23 is a key modulator of the immune response, making it an attractive target for the treatment of autoimmune disease. Correspondingly, several monoclonal antibodies against IL-23 are either in development or
Ting-ting Zhang, Junli Ma, Kenneth R. Durbin, T. Montavon, Susan E. Lacy, Gary J. Jenkins, S. Doktor, J. C. Kalvass   +7 more
semanticscholar   +1 more source

Anti‐drug antibodies of IL‐23 inhibitors for psoriasis: a systematic review

Journal of the European Academy of Dermatology and Venereology, 2022
Anti‐drug antibodies (ADAs) can form with certain biological medications, but their clinical significance is not fully understood. ADA formation in psoriasis patients treated with IL‐23 inhibitors was evaluated, looking at the incidence of ADAs, impact ...
A. Norden, J. Moon, S. Javadi, L. Munawar, J. Maul, J.J. Wu   +5 more
semanticscholar   +1 more source

Anti-IL-23 Phase II Data for Psoriasis: A Review.

Journal of drugs in dermatology : JDD, 2016
Monoclonal antibodies that target both Interleukin (IL)-12 and IL-23 have shown great efficacy in the treatment of psoriasis. Recent evidence suggests that IL-23 serves a more critical role than IL-12 in the pathogenesis of psoriasis, leading to the development of monoclonal antibodies that specifically target IL-23.We reviewed the results of the phase
Kourosh, Beroukhim, Melissa J, Danesh, Catherine, Nguyen, Annemieke, Austin, John, Koo, Ethan, Levin   +5 more
openaire   +1 more source

IL-17A inhibitor-induced ulcerative colitis treated with an anti-IL-23 antibody

Clinical Journal of Gastroenterology
Interleukin-17 (IL-17) has been suggested to have a protective effect on the intestinal mucosa. The administration of an anti-IL-17 receptor monoclonal antibody has been associated with the onset of inflammatory bowel disease. We present a case of ulcerative colitis caused by secukinumab, an anti-IL-17 receptor A monoclonal antibody, that was treated ...
Natsuki Ishida, Yusuke Asai, Tomohiro Takebe, Kenichi Takahashi, Kiichi Sugiura, Tomoharu Matsuura, Kazuo Kurihara, Takahiro Suzuki, Tetsuya Honda, Ken Sugimoto   +9 more
openaire   +2 more sources